CD163L1

Across TCGA pan-cancer cohorts, CD163L1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated CD163L1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD163L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CD163L1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and ESCA are the cancer types where CD163L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.320	0.653	.012	14	view →
UCEC	DFS	Median	All	0.914	0.608	.005	12	view →
ESCA	OS	Median	All	0.141	0.700	.001	9	view →
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
PRAD	DFS	Median	All	0.085	0.774	.007	6	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	6	view →
ACC	DFS	Median	All	0.140	0.666	.049	3	view →
BRCA	DFS	Median	All	0.227	0.528	.031	2	view →
SKCM	DFS	Median	All	0.515	0.637	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

CD163L1–HNSC (OS)

Open the HNSC breakdown →